The much-awaited launch of Mounjaro, an injectable drug used to treat obesity, overweight, and type 2 diabetes, has been ...

The single-dose vial presentation has marketing authorization from the national drugs regulator—Central Drugs Standard ...

Once-a-weekly, prescription-based medicine, Mounjaro is a single molecule that selectively binds to and activates both GIP ...

Eli Lilly has launched its diabetes and weight-loss drug Mounjaro in India after receiving regulatory approval. The launch ...

Global pharmaceutical company Eli Lilly and Company (India) has introduced Mounjaro (tirzepatide) in India, a breakthrough ...

Eli Lilly has launched its diabetes and weight-loss drug Mounjaro in India after receiving regulatory approval. With rising ...

Eli Lilly s Pleasant Prairie facility expansion gets final approval, paving the way for a 3 billion Kenosha County investment ...

Eli Lilly's much-anticipated drug for diabetes and obesity, that competes with Ozempic globally, is now in India-here's what ...

The drug has seen strong demand in the US and Europe, and its India launch is part of Lilly’s broader strategy to expand ...

The drug, typically taken once a week, would cost between Rs 14,000 and Rs 17,500 per month, depending on the dosage ...

Eli Lilly launches Mounjaro in India following drug regulator approval, targeting diabetes and weight-loss in a rapidly ...

Eli Lilly has launched its much-anticipated diabetes and weight-loss drug, Mounjaro (tirzepatide), in India, offering a new ...